Bifidobacterium lactis is a Gram-positive, anaerobic, non spore forming rod shaped bacterium.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT
Size
Price
Quantity
LBGF-0722-GF60
Product Information
Product Overview
Bifidobacterium lactis is a Gram-positive, anaerobic, non spore forming rod shaped bacterium.
Target
Bifidobacterium
Genus
Bifidobacterium
Application
Study and research
Culture Medium
BBL
Culture Conditions
37°C; Anaerobic
Risk Group
1
Product Format
Freeze-dried
Packaging
Ampoule tube
Storage
-80°C
Shelf Life
6 years
Target Introduction
Introduction
Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.
Alternative Names
Bifidobacterium lactis
FAQsPublished Data Customer Reviews Related Products
What is the recommended dosage for Bifidobacterium lactis in research?
The dosage can vary depending on the study, but commonly, it ranges from 1 to 10 billion CFUs per day. The exact dosage should be determined based on the specific objectives of the research and the target population.
What are the optimal growth conditions for Bifidobacterium lactis?
Bifidobacterium lactis thrives under anaerobic conditions at a temperature range of 37°C. The pH of the growth medium should be maintained around 6.5 to optimize bacterial proliferation and metabolic activity.
What are the stability considerations for Bifidobacterium lactis in different formulations?
Bifidobacterium lactis is stable in various formulations, including dairy products and dietary supplements. Encapsulation techniques can enhance its stability by protecting the bacteria from environmental stresses during processing and storage.
How should Bifidobacterium lactis cultures be prepared for experimental use?
Bifidobacterium lactis cultures should be prepared using freshly prepared, pre-reduced media under anaerobic conditions. The media should be devoid of oxygen to maintain the viability of the bacteria.
What are the common challenges in culturing Bifidobacterium lactis?
Common challenges include maintaining anaerobic conditions, preventing contamination, and ensuring consistent growth. Using high-quality, pre-reduced media and strict anaerobic techniques can help mitigate these challenges.
Concentration of TNF-a and IL-6 in the control (CONT) and probiotic (PROB) groups evaluated at the beginning of the study (T0) and after 45 d (T45) of milk ingestion
The study evaluated the effects of Bifidobacterium lactis HN019 on lipid profiles and cytokine levels in patients with metabolic syndrome (MetS). Fifty-one participants with MetS were divided into two groups: a control group (n=25) and a probiotic group (n=26) who consumed 80 mL of fermented milk containing B. lactis HN019 daily for 45 days. The results showed significant improvements in the probiotic group compared to the control group. There was a marked reduction in body mass index (BMI) (P=0.017), total cholesterol (TC) (P=0.009), and low-density lipoprotein cholesterol (LDL-C) (P=0.008). Furthermore, significant decreases in pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-α) (P=0.033) and interleukin-6 (IL-6) (P=0.044), were observed in the probiotic group. These findings suggest that B. lactis HN019 can positively influence lipid metabolism and reduce inflammation in individuals with MetS, thus potentially lowering cardiovascular risks. The reduction in BMI, TC, and LDL-C, coupled with the decreased levels of TNF-α and IL-6, underscores the therapeutic potential of B. lactis HN019 in managing metabolic syndrome.
Bernini, L. J., Simão, A. N. C., et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition. 2016, 32(6): 716-719.
Outstanding Probiotic Stability Bifidobacterium lactis from Creative Biolabs demonstrates exceptional stability and viability, significantly enhancing our probiotic research with consistent, reproducible results in gut health studies.
Superior Gut Microbiome Insights
Creative Biolabs' Bifidobacterium lactis is pivotal in our gut microbiome research, offering unparalleled consistency and high purity, outperforming other market alternatives.
Remarkable Efficacy in Immunomodulation
The use of Bifidobacterium lactis has substantially advanced our immunomodulation studies, providing reliable and effective results, surpassing similar products in scientific validity and reproducibility.
Excellent for Gut-Brain Axis Research Bifidobacterium lactis from Creative Biolabs has proven essential in gut-brain axis research, delivering consistent and high-quality data, making it a superior choice for our projects.
Enhanced Metabolic Health Studies
The exceptional purity and viability of Creative Biolabs' Bifidobacterium lactis have significantly improved our metabolic health research, offering reliable and reproducible outcomes.
Click the button below to contact us or submit your feedback about this product.
